Fibrogenic gene signature as early prediction for the efficacy of pharmacological interventions for MASH-associated fibrosis, part2

Background and aims: The incidence of metabolic dysfunction-associated steatohepatitis (MASH) and associated liver fibrosis is rapidly increasing, while pharmacological treatment options remain limited. Despite great efforts in developing novel MASH therapeutics, many investigative therapeutics that reduced fibrosis in preclinical models ultimately lacked efficacy in clinical trials. Therefore, we explored the possibility to predict the efficacy of investigative therapeutics on fibrogenic drive in the early stages of disease development and before effects on pathology become evident. Methods: Ldlr-/-.Leiden mice were fed a high-fat diet (HFD) to induce obesity and MASH. Mice were subsequently treated for four weeks with various therapeutics with established efficacy (obeticholic acid) or lack of efficacy (cenicriviroc, pioglitazone) to study their anti-fibrotic potential. Next, expression of a fibrogenic gene signature was evaluated, which predicts profibrotic processes preceding histopathologic fibrosis. The predictions were validated in parallel with a long-term experiment reaching histological fibrosis endpoints. Results: Cenicriviroc and pioglitazone did not affect HFD-induced fibrosis signature, indicative of no effect of these treatments on active fibrosis processes. Consistently, in the long-term treatment study, both cenicriviroc and pioglitazone did not affect HFD-induced histologically measured fibrosis. In contrast, obeticholic acid improved the early fibrogenic gene signature indicating a less fibrotic state compared with untreated HFD controls. These early gene expression changes aligned with long-term histological fibrosis endpoints and clinical data on these investigative therapeutics. Conclusions: This study highlights the potential of using short-term studies and applying a fibrogenic gene signature as an early screening tool to investigate the efficacy of investigative drugs on MASH-associated fibrosis. This signature, which is based on the active fibrosis processes in humans, may allow rapid screening of therapeutics and their combinations in translational mouse models to save time and resources. Overall design: Ldlr-/-.Leiden mice were fed a high-fat diet (HFD) to induce obesity and MASH. Control mice were continuously fed on standard Chow diet (C). Mice were subsequently treated for four weeks with various therapeutics with established efficacy (obeticholic acid = OCA; at either 10 or 20 mg/kg/day) or lack of efficacy (cenicriviroc = Ce, pioglitazone = Pi) to study their anti-fibrotic potential. Next, liver expression of a fibrogenic gene signature was evaluated. Note that this GEO entry (title, part2) only deals with a set of Chow, HFD, cenicriviroc and pioglitazone fed mice that were analysed in sequencing run 105831-001. Another GEO entry (title, part1) deals with a set of Chow, HFD and OCA fed mice that were analysed in sequencing run 104930-001.